주 메뉴 바로가기 본문 바로가기 하단 바로가기
  • Remsima®SC is the world's first SC formulation of biosimilar infliximab developed by Celltrion. It was approved by the European Medicines Agency(EMA).

    Remsima SC 제품이미지
    • Product Name : Remsima®SC
    • INN : Infliximab
    • Indications : Rheumatoid Arthritis(RA)
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is a common cause of autoimmune diseases.
    • Drug Approval Status : Europe(EU)

    This product description is for medical and educational purposes only.
    They are not intended to promote PR or sales campaigns.
    For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.

  • Remsima® is the world's first biosimilar monoclonal antibody developed by Celltrion. It was approved by international drug regulatory agencies across about 110 countries including the European Medicines Agency(EMA) and the U.S. Food and Drug Administration(FDA).

    Remsima image
    • Product Name : Remsima® / U.S. Product Name : Inflectra®
    • INN : Infliximab
    • Indications : Rheumatoid Arthritis(RA), Ankylosing Spondylitis(AS), Ulcerative Colitis(UC), Crohn’s disease(CD), Psoriatic Arthritis(PsA), Psoriasis
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is a common cause of autoimmune diseases.
    • Drug Approval Status : Korea, USA, Europe, Canada, Japan, etc.

    This product description is for medical and educational purposes only.
    They are not intended to promote PR or sales campaigns.
    For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.

  • Truxima® is the world's first oncology mAB biosimilar developed by Celltrion and approved by FDA and EMA.

    Truxima image
    • Product Name : Truxima®
    • INN : Rituximab
    • Indications : Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), Rheumatoid Arthritis(RA), Granulomatosis with Polyangiitis(GPA), Microscopic Polyangiitis(MPA)
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : It targets the CD20 antigen expressed on the surface of malignant B-cells and enabling the immune response that involves B-cell lysis.
    • Drug Approval Status : - Approved by EMA and MFDS : Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), Rheumatoid Arthritis(RA), Granulomatosis with Polyangiitis(GPA), Microscopic Polyangiitis(MPA) - Approved by FDA : NHL, CLL

    This product description is for medical and educational purposes only.
    They are not intended to promote PR or sales campaigns.
    For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.

  • Herzuma® is an oncology mAb biosimilar developed by Celltrion and approved by FDA and EMA.

    Herzuma image
    • Product Name : Herzuma®
    • INN : Trastuzumab
    • Indications : HER2-Positive Metastatic Breast Cancer, Early Breast Cancer(EBC), Metastatic Gastric Cancer(MGC)
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : It binds to the HER2 receptor overexpressed on the surface of breast cancer cells, as an antibody, to prevent the proliferation and rapid growth of breast cancer cells.
    • Drug Approval Status : Korea, USA, Europe, Japan, Brazil, etc.

    This product description is for medical and educational purposes only.
    They are not intended to promote PR or sales campaigns.
    For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.